Evidence map›Paper›PMID 39840863›Full record

ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025

HER2 Status in Gastric and Gastroesophageal Carcinomas: Evaluation of Histopathological Fingings, Paired ResectionBiopsy Specimens, and the Effect of Neoadjuvant Therapy: A Single Center Study.

Resmiye Irmak Yuzuguldu, Ozgul Sagol, Mehtat Unlu, Merve Keskinkilic, Serhan Derici, Hale Akpinar, Sulen Sarioglu

Abstract read
In one paragraph

Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Resmiye Irmak YuzugulduDepartment of Medical Pathology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Ozgul SagolDepartment of Medical Pathology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Mehtat UnluDepartment of Medical Pathology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Merve KeskinkilicDivision of Medical Oncology, Department of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Serhan DericiDepartment of General Surgery, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Hale AkpinarDivision of Gastroenterohepatology, Department of Internal Medicine, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.
Sulen SariogluDepartment of Medical Pathology, Dokuz Eylül University Faculty of Medicine, İzmir, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/Aims: Accurately determining the human epidermal growth factor receptor 2 (HER2) status is crucial in identifying suitable candidates for targeted therapy in gastric cancer, considering the cost and potential side effects of anti-HER2 treatments. This study aimed to assess HER2 overexpression/amplification prevalence in gastric and gastroesophageal cancer patients, its correlation with clinicopathological characteristics, and the consistency of HER2 status between biopsy and radical specimens. Materials and Methods: We analyzed data from 667 specimens of 600 gastric/gastroesophageal cancer patients at Dokuz Eylül University Faculty of Medicine from 2012 to 2021. The correlation of HER2 expression and amplification status and clinicopathological parameters were assessed. Furthermore, we compared HER2 status concordance between paired biopsy-radical specimens when both endoscopic and radical materials were present. Additionally, we compared HER2 status before and after treatment in patients receiving neoadjuvant chemotherapy. Results: In our study, +3 HER2 immunohistochemistry results were more common in gastroesophageal junction tumors (23%). Human epidermal growth factor receptor 2 immunohistochemistry positivity and HER2 gene amplification were found to be significantly more common in males, people over 65 years of age, and intestinal morphology. Overall concordance of HER2 status between radical and biopsy materials was 95.5%. Conclusion: The high HER2 concordance between the paired biopsy and radical samples holds significant importance in clinical management. This finding is particularly noteworthy since the HER2 assessment can generally be conducted on small/limited biopsy materials in routine practice. Our study is the most extensive series from Türkiye and the Balkans, which will shed light on our country's data by investigating the relationship of HER2 with clinicopathological parameters in gastric/gastroesophageal carcinomas.

Indexed as

Erb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsEsophagogastric JunctionNeoadjuvant TherapyStomach NeoplasmsAdultAgedAged, 80 and overBiopsyFemaleGene AmplificationHumansImmunohistochemistryMaleMiddle AgedERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesgastric carcinomasHER2in situ hybridization

Identifiers

PMID39840863
PMCPMC12147396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.